Rivaroxaban in breast milk after childbirth
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at how a blood thinner called rivaroxaban enters breast milk after delivery. It may help women who need this medication while breastfeeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are within 6 weeks of giving birth
- You have a high risk of blood clots (high body mass index or personal clot history)
- You are not breastfeeding, or you are breastfeeding a full-term healthy baby
- You are 18 or older and speak English
- You do not have active bleeding or kidney or liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood-thinner medicines given after a C-section to see which one works better at preventing dangerous blood clots. It may help women who are at higher risk for clots rest easier right after delivery.
This trial compares two blood-thinning medicines (apixaban and enoxaparin) to prevent dangerous blood clots after childbirth. If you are at higher risk for clots but not breastfeeding, you may be able to take part.
This trial is testing a short course of a low-dose blood thinner (heparin) to prevent dangerous blood clots in the legs or lungs after childbirth. It is for women who have certain risk factors that make clots more likely.
This trial is testing the drug rivaroxaban in children aged 2 to 17 who have large bulges (aneurysms) in their heart arteries after Kawasaki disease. It aims to see how the drug works in the body to prevent blood clots.
This study looks at how a blood thinner called rivaroxaban is used in babies under 2 who have had a blood clot. It aims to understand safety and patterns of use to help guide treatment for young children.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
Hear when a new Postpartum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.